Biora Therapeutics

Biora Therapeutics is a clinical-stage biotech innovating oral drug delivery systems designed to replace injectable biologics. The company is advancing two primary platforms: the BioJet™ platform for systemic, needle-free delivery of large molecules like GLP-1 agonists, and the NaviCap™ platform for targeted delivery of therapeutics to specific GI tract sites. While demonstrating promising preclinical and early clinical data, the company has recently undergone significant financial restructuring, including a Chapter 11 sale process completed in early 2025, to position itself for future growth. Its technology aims to address major compliance and accessibility challenges in treating chronic conditions.

BioJet™: Needle-free oral systemic delivery platform for large molecules. NaviCap™: Targeted oral delivery platform for localized release in the gastrointestinal tract.

Biora operates in the competitive field of alternative biologic delivery, facing competition from other biotechs developing oral, inhalable, or transdermal delivery technologies, as well as large pharmaceutical companies investing in similar platforms. Success will depend on demonstrating superior efficacy, reliability, and a compelling value proposition.